Modified peptide interfering with FOXO4–p53 interaction (senolytic research)
Proxofim
An experimental D-retro-inverso peptide studied for selective clearance of senescent cells in preclinical models.
- Evidence:
- Preclinical evidence primarily
- Status:
- Research-stage
- Reviewed:
- 2026-08-03
Also known as: Proxofim, FOXO4-D-Retro-Inverso
What is Proxofim?
An experimental D-retro-inverso peptide studied for selective clearance of senescent cells in preclinical models.
This profile is educational. It organizes publicly discussed research context for Proxofim and related naming aliases — it is not a treatment guide.
Proposed mechanism
Disrupts FOXO4–p53 binding in senescent cells, proposed to trigger apoptosis of senescent cells while sparing healthy cells in models.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Preclinical evidence primarily
Preclinical evidence grade: Early-stage human research
FOXO4-DRI (Proxofim) gained attention after mouse aging/senolytic studies. Human clinical evidence is essentially absent. Product quality and sequence authenticity are major concerns in research-chemical markets.
Key uncertainties
- Human translation
- Long-term effects of senescent-cell clearance
Research areas being studied
- Senolytics
- Aging biology
- Cellular senescence
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Not characterized in humans
Additional risks & considerations
- Unknown human toxicity
- Product authenticity concerns
Regulatory status
Research-stage
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is Proxofim?
An experimental D-retro-inverso peptide studied for selective clearance of senescent cells in preclinical models.
How does Proxofim work (proposed mechanism)?
Disrupts FOXO4–p53 binding in senescent cells, proposed to trigger apoptosis of senescent cells while sparing healthy cells in models.
What is Proxofim being researched for?
Proxofim has been discussed in research contexts including: Senolytics, Aging biology, Cellular senescence.
What does current evidence say about Proxofim?
Preclinical evidence primarily. FOXO4-DRI (Proxofim) gained attention after mouse aging/senolytic studies. Human clinical evidence is essentially absent. Product quality and sequence authenticity are major concerns in research-chemical markets.
What safety considerations are noted for Proxofim?
Reported or discussed considerations include: Not characterized in humans; Unknown human toxicity; Product authenticity concerns. This is educational information, not medical advice.
References & sources
- Baar MP et al. (2017). FOXO4-DRI selectively targets senescent cells — Cell. Evidence type: animal.
Prefer interactive tools? Open the PepGuide library entry for Proxofim or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.